Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)

Riechelmann, R.Srimuninnimit, V.Kavan, P.Di Bartolomeo, M.Maiello, E.Cicin, I.Kroening, H.2024-06-122024-06-1220160923-75341569-8041https://doi.org/10.1093/annonc/mdw370.100https://hdl.handle.net/20.500.14551/2576641st Annual Congress of the European-Society-for-Medical-Oncology (ESMO) -- OCT 07-11, 2016 -- Copenhagen, DENMARK[Abstract Not Available]en10.1093/annonc/mdw370.100info:eu-repo/semantics/openAccess[No Keywords]Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)Conference Object27Q1WOS:000393912500460